<DOC>
	<DOC>NCT00402103</DOC>
	<brief_summary>To assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg / amlodipine 10 mg in patients with essential hypertension (Mean Sitting Diastolic Blood Pressure [msDBP] ≥ 90 mmHg and &lt; 110 mmHg).</brief_summary>
	<brief_title>An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Outpatients 18 years of age or older Male or female patients are eligible For newly diagnosed/untreated patients with essential hypertension defined as msDBP ≥ 90 and &lt; 110 mmHg at Visit 1 and Visit 4 For previously treated patients with essential hypertension defined as msDBP ≥ 90 and &lt; 110 mmHg after 2 to 4 weeks of washout (Visit 4) Severe hypertension History or evidence of a secondary form of hypertension History of Hypertensive encephalopathy or cerebrovascular accident. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Hypertension, aliskiren, amlodipine, HCTZ, blood pressure</keyword>
</DOC>